- EGFR Signaling Pathway
- TGF-beta Signaling
- Canonical Wnt Signaling
- non-Canonical Wnt Signaling
- Notch Signaling
- p53 Pathway
- NF-kB Pathway
- Cytokine Signaling
Dr. Daniel I.C. Wang is an Institute Professor at Massachusetts Institute of Technology and Termasek Professor at the National University of Singapore. He is a member of National Academy of Engineering, American Academy of Arts and Sciences, Academia Sinica, American Institute of Medical and Biological Engineering, and International Institute of Biotechnology. He received his MS degree from MIT, and Ph.D. from University of Pennsylvania. He also received honorary doctorates from Hong Kong University of Science and technology, the Catholic University Valparaiso, Chile, and Honorary Professorships from Peking Union Medical College, China, and Zhejiang University, China. Dr. Wang also won numerous prestigious awards including the Amgen Award from the Engineering Foundation, Food, Pharmaceutical and Bioengineering Award and William H. Walker Award from AICHE.
Over 40 years of pioneering and innovative research in the field of biotechnology and biochemical engineering, Prof. Wang has made profound impact on the biotechnology industry scientific research, and education. He founded and directed the NSF funded Biotechnology Process Engineering Center for more than 10 years. He was the editor-in-chief for Biotechnology and Bioengineering for more than 10 years. He resides and has resided as editorial board members for 8 scientific journals. His research interests and contribution to the biotech industry include mammalian cell culture, microbial fermentation, protein purification and refolding, bioreactor engineering, production of recombinant proteins, bioprocess monitoring and control, glycoprotein quality, protein stabilization, enzyme technology, and cellulosic Biomass conversion. He has authored 5 books, over 230 research publications, and 15 patents. He has consulted for over 50 companies worldwide and was on the board of directors and scientific advisory boards on a number of public and private companies.
Dr. Xie obtained his doctor degree from the Biotechnology Process Engineering Center at Massachusetts Institute of Technology under the supervision of Prof. Daniel I.C. Wang. At MIT, Dr. Xie developed a stoichiometric model to optimize the design of mammalian cell culture medium and the control of the dynamic culture environment. In 1994, he was able to achieve a record cell density of 1.7 x 107 cells/ml and a record antibody titer of 2.4 gram/L. He then worked on viral vaccine process development and cGMP manufacturing for three US FDA approved products (Varicella® , Zostervax® , and ProQuad® ) at Merck Research Laboratory, Merck & Company. He also led the cell culture and viral vaccine process development and cGMP clinical production for Merck’s adenovirus based HIV vaccine and helped to develop by far the largest scale (2000L) of human viral vaccine process under serum-free condition in stirred-tank bioreactors. He is also the director and professor at the Cell Culture R&D center at the Peking Union Medical College since 2002.
Dr. Ma obtained his doctor degree from Ohio State University under the supervision of worldwide fluid dynamic and shear force expert, Prof. Jeff Chalmers. He did extensive studies on fluid dynamics and the effects of shear force in a stirred-tank bioreactor on mammalian cells. He also developed models for mammalian cell process scale-up. Dr. Ma worked at Pfizer for many years with increasing responsibilities. He led the development and scale-up (from 1L to 15,000 L) of a robust state-of-the-art protein-free chemically-defined cell culture process platform for monoclonal antibody product development and commercial manufacturing. His expertise includes culture medium development, fed-batch process development, process scale-up, cGMP pilot scale (500L-5000L cell culture scale) clinical production, and 15,000 L cell culture scale commercial manufacturing. Owing to his major contributions to Pfizer’s recombinant protein and monoclonal antibody product development, Dr. Ma received several awards including the Pfizer’s Global R&D Achievement Award and became the youngest receiver for this award in Pfizer’s history.
Dr. Wang received his doctor degree from University of Oregon. He completed three-year post-doctoral work at Princeton University. After three years of working as research scientist at Massachusetts Institute of Technology, he jointed Merck Research Laboratories. For over 13 years, Dr. Wang worked in the area of quality control and bioanalytical development support for vaccine and therapeutic protein development, and participated in and led numerous projects of developing candidates and marketing vaccine. From 1998 to 2005, he led the analytical development effort for Merck's Gardasil quality control and analytical development, leading to the successful licensure of the quadra-valent vaccine product in many countries. His expertise covers quality control and structural characterization development, method validation, analytical technology transfer, formulation development, and GMP quality system. He published over 60 peer-reviewed scientific papers, and 6 PCT patents, as well as received numerous awards from Merck and the award of outstanding industrial biotechnology award from American Chemical Society.